1. Home
  2. SPRO vs INGN Comparison

SPRO vs INGN Comparison

Compare SPRO & INGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • INGN
  • Stock Information
  • Founded
  • SPRO 2013
  • INGN 2001
  • Country
  • SPRO United States
  • INGN United States
  • Employees
  • SPRO N/A
  • INGN N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • INGN Industrial Specialties
  • Sector
  • SPRO Health Care
  • INGN Health Care
  • Exchange
  • SPRO Nasdaq
  • INGN Nasdaq
  • Market Cap
  • SPRO 162.1M
  • INGN 182.8M
  • IPO Year
  • SPRO 2017
  • INGN 2014
  • Fundamental
  • Price
  • SPRO $2.18
  • INGN $6.55
  • Analyst Decision
  • SPRO Buy
  • INGN Strong Buy
  • Analyst Count
  • SPRO 4
  • INGN 3
  • Target Price
  • SPRO $5.00
  • INGN $11.00
  • AVG Volume (30 Days)
  • SPRO 784.3K
  • INGN 163.7K
  • Earning Date
  • SPRO 08-12-2025
  • INGN 08-07-2025
  • Dividend Yield
  • SPRO N/A
  • INGN N/A
  • EPS Growth
  • SPRO N/A
  • INGN N/A
  • EPS
  • SPRO N/A
  • INGN N/A
  • Revenue
  • SPRO $44,584,000.00
  • INGN $339,960,000.00
  • Revenue This Year
  • SPRO N/A
  • INGN $7.47
  • Revenue Next Year
  • SPRO N/A
  • INGN $6.22
  • P/E Ratio
  • SPRO N/A
  • INGN N/A
  • Revenue Growth
  • SPRO N/A
  • INGN 5.73
  • 52 Week Low
  • SPRO $0.51
  • INGN $5.70
  • 52 Week High
  • SPRO $3.22
  • INGN $13.33
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 32.49
  • INGN 44.54
  • Support Level
  • SPRO $2.30
  • INGN $6.27
  • Resistance Level
  • SPRO $2.45
  • INGN $6.93
  • Average True Range (ATR)
  • SPRO 0.11
  • INGN 0.26
  • MACD
  • SPRO -0.07
  • INGN -0.02
  • Stochastic Oscillator
  • SPRO 2.03
  • INGN 28.28

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About INGN Inogen Inc

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Share on Social Networks: